Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hang Quach

Showing results (11-20 of 119) with videos related to

Pageof 12
Sort By:
Drugs & Aging|September 28, 2007
Treatment strategies in elderly patients with multiple myeloma: current statusHang Quach, H Miles Prince, Linda Mileshkin
Immunotherapy|July 20, 2010
Drug-mediated and cellular immunotherapy in multiple myelomaDavid S Ritchie, Hang Quach, Kate Fielding, et al.
Haematologica|September 11, 2025
Response to Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with haematological malignanciesMatthew J Rees, Hang Quach, Darren Jardine, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 11, 2022
Nutrition support use and clinical outcomes in patients with multiple myeloma undergoing autologous stem cell transplantJulia Kuypers, Natalie Simmance, Hang Quach, et al.
Haematologica|October 19, 2023
Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patientsSlavisa Ninkovic, Louise E Purton, Simon J Harrison, et al.
Internal Medicine Journal|June 26, 2023
Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experienceShirlene Sim, Hang Quach, Tina Pham, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2024
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple MyelomaHang Quach, Gurdeep Parmar, Maria-Victoria Mateos, et al.
Mycoses|September 5, 2020
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort studyChhay Lim, Priyadarshini Sinha, Simon J Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2021
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation TherapiesChhay Lim, Priyadarshini Sinha, Simon J Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 22, 2023
Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory StudyHayley Beer, Holly Chung, Simon J Harrison, et al.
Pageof 12

Showing results (11-20 of 119) with videos related to

Sort By:
Pageof 12
Drugs & Aging|September 28, 2007
Treatment strategies in elderly patients with multiple myeloma: current statusHang Quach, H Miles Prince, Linda Mileshkin
Immunotherapy|July 20, 2010
Drug-mediated and cellular immunotherapy in multiple myelomaDavid S Ritchie, Hang Quach, Kate Fielding, et al.
Haematologica|September 11, 2025
Response to Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with haematological malignanciesMatthew J Rees, Hang Quach, Darren Jardine, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 11, 2022
Nutrition support use and clinical outcomes in patients with multiple myeloma undergoing autologous stem cell transplantJulia Kuypers, Natalie Simmance, Hang Quach, et al.
Haematologica|October 19, 2023
Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patientsSlavisa Ninkovic, Louise E Purton, Simon J Harrison, et al.
Internal Medicine Journal|June 26, 2023
Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experienceShirlene Sim, Hang Quach, Tina Pham, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2024
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple MyelomaHang Quach, Gurdeep Parmar, Maria-Victoria Mateos, et al.
Mycoses|September 5, 2020
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort studyChhay Lim, Priyadarshini Sinha, Simon J Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2021
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation TherapiesChhay Lim, Priyadarshini Sinha, Simon J Harrison, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 22, 2023
Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory StudyHayley Beer, Holly Chung, Simon J Harrison, et al.
Pageof 12